Development of nanoaptamers using a mesoporous silica model labeled with (99m)tc for cancer targeting.

Abstract

The use of mesoporous silica in targeted cancer therapy is increasing daily. The combination of a rigid model of nanoparticles like mesoporous silica and biological compounds with an affinity for oncological diseases is the most promising drug-targeting system nowadays. In this study, we used the mesoporous silica SBA-15 combined with aptamer (functionalized for tumor with MUC1). The results obtained were of interest and showed the formation of the silica mesoporous structure. The impregnation methodology of mesoporous silica with the aptamer was also confirmed. Cytotoxicity results demonstrated that the particle associated with the aptamer has no cytotoxicity. We conclude that although further studies are required, the mesoporous silica nanoparticle model loaded with aptamer is very functional and can be used for other applications, especially in nuclear medicine.

• Authors: Lucas Torres Miranda Sá, Claudia Pessoa, Assuero Silva Meira, Maria Isabel Pais da Silva, Sotiris Missailidis, Ralph Santos-Oliveira
• Journal: Oncology (Oncology) Vol. 82 Issue 4 Pg. 213-7 ( 2012) ISSN: 1423-0232 [Electronic] Switzerland
• PMID: 22508189 (Publication Type: Journal Article)
• Copyright: Copyright © 2012 S. Karger AG, Basel.

Chemical References

• Aptamers, Nucleotide
• Biomarkers, Tumor
• SBA-15
• Silicon Dioxide

Topics

• Aptamers, Nucleotide (therapeutic use)
• Biomarkers, Tumor (antagonists & inhibitors, metabolism)
• Cell Line, Tumor
• Drug Delivery Systems
• Humans
• Models, Biological
• Nanoparticles
• Neoplasms (drug therapy)
• Silicon Dioxide (therapeutic use)